Valuation: Insulet Corporation

Market Cap 10.83B 9.72B 8.88B 8.11B 15.3B 1,017B 15.78B 107B 42.7B 543B 40.65B 39.78B 1,716B P/E 2026 *
25.6x
P/E 2027 * 20.5x
Enterprise Value 10.88B 9.77B 8.92B 8.15B 15.37B 1,022B 15.85B 108B 42.89B 545B 40.84B 39.96B 1,724B EV / Sales 2026 *
3.3x
EV / Sales 2027 * 2.83x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day-6.16%
1 week-3.93%
Current month-2.12%
1 month+8.03%
3 months+9.94%
6 months-12.55%
Current year-48.46%
1 week 143.28
Extreme 143.282
168.47
1 month 132.86
Extreme 132.855
168.47
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 126.4
Extreme 126.4
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 32.12
Extreme 32.12
354.88
Manager TitleAgeSince
Chief Executive Officer 55 27/04/2025
Director of Finance/CFO 53 29/09/2025
Compliance Officer 50 30/11/2022
Director TitleAgeSince
Director/Board Member 61 26/07/2015
Director/Board Member 54 19/10/2020
Director/Board Member 55 17/10/2021
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Tax

Chief Financial Officer

-1,882 0.0027%
30/09/26 Free

Director

141 0.0002%
30/09/26 Free

Director

178 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-6.16%-3.93%-53.41%-9.88% 10.83B
-3.23%+5.13%-11.73%+14.70% 197B
-2.75%+4.53%-8.89%+17.97% 128B
-2.90%+4.83%+12.61%+40.30% 128B
+0.96%+8.75%-38.73%+11.23% 99B
-1.80%+0.92%-5.77%+70.91% 64.82B
-0.78%+6.83%+20.12%-18.16% 58.17B
+0.79%+17.37%-6.13%+57.47% 52.84B
-6.98%-14.94%-9.70%+46.32% 50.69B
-2.36%+4.32%+2.44%-8.53% 37.23B
Average -2.52%+6.57%-9.92%+22.23% 82.62B
Weighted average by Cap. -2.29%+7.50%-7.46%+24.17%

Financials

2026 *2027 *
Net sales 3.3B 2.96B 2.7B 2.47B 4.66B 310B 4.8B 32.58B 13B 165B 12.37B 12.11B 522B 3.72B 3.34B 3.05B 2.79B 5.25B 349B 5.42B 36.74B 14.66B 186B 13.96B 13.66B 589B
Net income 425M 382M 349M 319M 601M 39.92B 620M 4.2B 1.68B 21.32B 1.6B 1.56B 67.36B 534M 479M 438M 400M 754M 50.13B 778M 5.28B 2.1B 26.77B 2B 1.96B 84.58B
Net Debt 49.62M 44.54M 40.69M 37.17M 70.11M 4.66B 72.3M 490M 196M 2.49B 186M 182M 7.86B -322M -289M -264M -241M -455M -30.27B -470M -3.19B -1.27B -16.16B -1.21B -1.18B -51.07B
Projected Income Statement - Annual - Insulet Corporation
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
06/11/26 US$146.51 -6.16% 1,567,691
05/11/26 US$156.12 -5.39% 1,319,327
04/11/26 US$165.02 +6.56% 2,604,117
03/11/26 US$154.86 +0.81% 1,619,642
02/11/26 US$153.61 +2.63% 1,772,579
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Insulet Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
156.12USD
Average target price
168.48USD
Spread / Average Target
+7.92%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Insulet Corporation
  1. Stock Market
  2. Stocks
  3. PODD Stock